MUCL1 and neoplasm: This analysis revealed that most long-term survivors, over 12 months, had higher antibody titers (Fig. 5A) against several tumor associated antigens, such as mucin proteins MUCL-1 [21], MUC3B [22] and the cancer testis antigen POTEE [23] at baseline, than patients who survived for less than 1 year.